Autoantibodies against monomeric C-reactive protein in sera from patients with lupus nephritis are associated with disease activity and renal tubulointerstitial lesions

Human Immunology

Volumn 69, Issue 12, 2008, Pages 840-844

  Tan, Ying ^a   Yu, Feng ^a   Yang, Haizhen ^a   Chen, Min ^a   Fang, Qiying ^a   Zhao, Ming hui ^a  

^a PEKING UNIVERSITY FIRST HOSPITAL   (China)

Author keywords

Activity index; Chronicity index; Lupus nephritis; mCRP autoantibodies

Indexed keywords

AUTOANTIBODY; C REACTIVE PROTEIN; IMMUNOGLOBULIN G ANTIBODY; MONOMERIC C REACTIVE PROTEIN AUTOANTIBODY; UNCLASSIFIED DRUG;

ACUTE KIDNEY FAILURE; ADULT; ANTIBODY SCREENING; ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIBROSING ALVEOLITIS; HUMAN; INTERSTITIAL NEPHRITIS; KIDNEY BIOPSY; LABORATORY TEST; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALE; PARTIAL THROMBOPLASTIN TIME; PREVALENCE; PRIORITY JOURNAL; SCORING SYSTEM; SYSTEMIC LUPUS ERYTHEMATOSUS; URINALYSIS;

ADULT; AUTOANTIBODIES; BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; DISEASE PROGRESSION; FEMALE; HUMANS; KIDNEY; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; PROGNOSIS; REMISSION, SPONTANEOUS; SEVERITY OF ILLNESS INDEX;

EID: 57649104244     PISSN: 01988859     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.humimm.2008.09.006     Document Type: Article

References (57)

1. Zuhre N.T., and Kalunian K.C. The definition and classification of systemic lupus erythematosus. 7th ed. (2007), Lippincott Williams & Wilkins, Philadelphia
2. Sherer Y., Gorstein A., Fritzler M.J., et al. Autoantibody explosion in systemic lupus erythematosus: more than 100 different antibodies found in SLE patients. Semin Arthritis Rheum 34 (2004) 501-537
3. Sherer Y, Fritzler MJ, Shoenfeld Y. Autoantibody explosion in lupus-155 different autoantibodies in SLE. Proceedings of the 8th International Congress on SLE, Shanghai, China, 2007.
4. Arbuckle M.R., McClain M.T., Rubertone M.V., et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 349 (2003) 1526-1533
5. Stinton L.M., Barr S.G., Tibbles L.A., et al. Autoantibodies in lupus nephritis patients requiring renal transplantation. Lupus 16 (2007) 394-400
6. Toubi E., and Shoenfeld Y. Protective autoimmunity in cancer (review). Oncol Rep 17 (2007) 245-251
7. Liu G., Ma X.Z., Zou W.Z., et al. The prevalence of biopsy-proven renal diseases in adults between two periods over the past 10 years. J Clin Intern Med 21 (2004) 834-838
8. Moroni G., Trendelenburg M., Del Papa N., et al. Anti-C1q antibodies may help in diagnosing a renal flare in lupus nephritis. Am J Kidney Dis 37 (2001) 490-498
9. Riboldi P., Gerosa M., Moroni G., et al. Anti-DNA antibodies: a diagnostic and prognostic tool for systemic lupus erythematosus?. Autoimmunity 38 (2005) 39-45
10. Renaudineau Y., Deocharan B., Jousse S., et al. Anti-alpha-actinin antibodies: a new marker of lupus nephritis. Autoimmun Rev 6 (2007) 464-468
11. Yasojima K., Schwab C., McGeer E.G., et al. Human neurons generate C-reactive protein and amyloid P: upregulation in Alzheimer's disease. Brain Res 887 (2000) 80-89
12. Kuta A.E., and Baum L.L. C-reactive protein is produced by a small number of normal human peripheral blood lymphocytes. J Exp Med 164 (1986) 321-326
13. Calabro P., Willerson J.T., and Yeh E.T. Inflammatory cytokines stimulated C-reactive protein production by human coronary artery smooth muscle cells. Circulation 108 (2003) 1930-1932
14. Dong Q., and Wright J.R. Expression of C-reactive protein by alveolar macrophages. J Immunol 156 (1996) 4815-4820
15. Jabs W.J., Logering B.A., Gerke P., et al. The kidney as a second site of human C-reactive protein formation in vivo. Eur J Immunol 33 (2003) 152-161
16. Potempa L.A., Zeller J.M., Fiedel B.A., et al. Stimulation of human neutrophils, monocytes, and platelets by modified C-reactive protein (CRP) expressing a neoantigenic specificity. Inflammation 12 (1988) 391-405
17. Potempa L.A., Maldonado B.A., Laurent P., et al. Antigenic, electrophoretic and binding alterations of human C-reactive protein modified selectively in the absence of calcium. Mol Immunol 20 (1983) 1165-1175
18. Kravitz M.S., Pitashny M., and Shoenfeld Y. Protective molecules-C-reactive protein (CRP), serum amyloid P (SAP), pentraxin3 (PTX3), mannose-binding lectin (MBL), and apolipoprotein A1 (Apo A1), and their autoantibodies: prevalence and clinical significance in autoimmunity. J Clin Immunol 25 (2005) 582-591
19. Wang H.W., and Sui S.F. Dissociation and subunit rearrangement of membrane-bound human C-reactive proteins. Biochem Biophys Res Commun 288 (2001) 75-79
20. Rees R.F., Gewurz H., Siegel J.N., et al. Expression of a C-reactive protein neoantigen (neo-CRP) in inflamed rabbit liver and muscle. Clin Immunol Immunopathol 48 (1988) 95-107
21. Diehl E.E., Haines III G.K., Radosevich J.A., et al. Immunohistochemical localization of modified C-reactive protein antigen in normal vascular tissue. Am J Med Sci 319 (2000) 79-83
22. Schwedler S.B., Guderian F., Dammrich J., et al. Tubular staining of modified C-reactive protein in diabetic chronic kidney disease. Nephrol Dial Transplant 18 (2003) 2300-2307
23. Shine B., de Beer F.C., and Pepys M.B. Solid phase radioimmunoassays for human C-reactive protein. Clin Chim Acta 117 (1981) 13-23
24. Williams Jr. R.C., Harmon M.E., Burlingame R., et al. Studies of serum C-reactive protein in systemic lupus erythematosus. J Rheumatol 32 (2005) 454-461
25. Barnes E.V., Narain S., Naranjo A., et al. High sensitivity C-reactive protein in systemic lupus erythematosus: relation to disease activity, clinical presentation and implications for cardiovascular risk. Lupus 14 (2005) 576-582
26. Sjöwall C., Eriksson P., Almer S., et al. Autoantibodies to C-reactive protein is a common finding in SLE, but not in primary Sjogren's syndrome, rheumatoid arthritis or inflammatory bowel disease. J Autoimmun 19 (2002) 155-160
27. Bell S.A., Faust H., Schmid A., et al. Autoantibodies to C-reactive protein (CRP) and other acute-phase proteins in systemic autoimmune diseases. Clin Exp Immunol 113 (1998) 327-332
28. Sjowall C., Bengtsson A.A., Sturfelt G., et al. Serum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosus. Arthritis Res Ther 6 (2004) R87-R94
29. Figueredo M.A., Rodriguez A., Ruiz-Yag̈ue M., et al. Autoantibodies against C-reactive protein: clinical associations in systemic lupus erythematosus and primary antiphospholipid syndrome. J Rheumatol 33 (2006) 1980-1986
30. Rosenau B.J., and Schur P.H. Antibodies to C reactive protein. Ann Rheum Dis 65 (2006) 674-676
31. Hochberg M.C. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40 (1997) 1725
32. Weening J.J., D'Agati V.D., Schwartz M.M., et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. Kidney Int 65 (2004) 521-530
33. Szalai A.J., Nataf S., Hu X.Z., et al. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 168 (2003) 5792-5797
34. Rodriguez W., Mold C., Kataranovski M., et al. Reversal of ongoing proteinuria in autoimmune mice by treatment with C-reactive protein. Arthritis Rheum 52 (2005) 642-650
35. Trouw L.A., Groeneveld T.W., Seelen M.A., et al. Anti-C1q autoantibodies deposit in glomeruli but are only pathogenic in combination with glomerular C1q-containing immune complexes. J Clin Invest 114 (2004) 679-688
36. Zuniga R., Markowitz G.S., Arkachaisri T., et al. Identification of IgG subclasses and C-reactive protein in lupus nephritis: the relationship between the composition of immune deposits and FCγ receptor type IIA alleles. Arthritis Rheum 48 (2003) 460-470
37. Devaraj S., Venugopal S., and Jialal I. Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis 184 (2006) 48-52
38. Ballou S.P., and Macintyre S.S. Absence of a binding reactivity of human C-reactive protein for immunoglobulin or immune complexes. J Lab Clin Med 115 (1990) 332-338
39. Tilg H., Vannier E., Vachino G., et al. Antiinflammatory properties of hepatic acute phase proteins: preferential induction of interleukin 1 (IL-1) receptor antagonist over IL-1 beta synthesis by human peripheral blood mononuclear cells. J Exp Med 178 (1993) 1629-1636
40. Crowell R.E., Du Clos T.W., Montoya G., et al. C-reactive protein receptors on the human monocytic cell line U-937. Evidence for additional binding to Fc gamma RI. J Immunol 147 (1991) 3445-3451
41. Szalai A.J., Nataf S., Hu X.Z., et al. Experimental allergic encephalomyelitis is inhibited in transgenic mice expressing human C-reactive protein. J Immunol 168 (2002) 5792-5797
42. Zouki C., Haas B., Chan J.S., et al. Loss of pentameric symmetry of C-reactive protein is associated with promotion of neutrophil-endothelial cell adhesion. J Immunol 167 (2001) 5355-5361
43. Khreiss T., Jozsef L., Hossain S., et al. Loss of pentameric symmetry of C-reactive protein is associated with delayed apoptosis of human neutrophils. J Biol Chem 277 (2002) 40775-40781
44. Khreiss T., Jozsef L., Potempa L.A., et al. Conformational rearrangement in C-reactive protein is required for proinflammatory actions on human endothelial cells. Circulation 109 (2004) 2016-2022
45. Zhong Y., Li S.H., Liu S.M., et al. C-Reactive protein upregulates receptor for advanced glycation end products expression in human endothelial cells. Hypertension 48 (2006) 504-511
46. Schwedler S.B., Amann K., Wernicke K., et al. Native C-reactive protein increases whereas modified C-reactive protein reduces atherosclerosis in apolipoprotein E-knockout mice. Circulation 112 (2005) 1016-1023
47. Khreiss T., Jozsef L., Potempa L.A., et al. Loss of pentameric symmetry in C-reactive protein induces interleukin-8 secretion through peroxynitrite signaling in human neutrophils. Circ Res 97 (2005) 690-697
48. Devaraj S., Venugopal S., and Jialal I. Native pentameric C-reactive protein displays more potent pro-atherogenic activities in human aortic endothelial cells than modified C-reactive protein. Atherosclerosis 184 (2006) 48-52
49. Ji S.R., Wu Y., Zhu L., et al. Cell membranes and liposomes dissociate C-reactive protein (CRP) to form a new, biologically active structural intermediate: mCRP(m). Faseb J 21 (2007) 284-294
50. Schwedler S.B., Filep J.G., Galle J., et al. C-reactive protein: a family of proteins to regulate cardiovascular function. Am J Kidney Dis 47 (2006) 212-222
51. Ji S.R., Wu Y., Potempa L.A., et al. Effect of modified C-reactive protein on complement activation: a possible complement regulatory role of modified or monomeric C-reactive protein in atherosclerotic lesions. Arterioscler Thromb Vasc Biol 26 (2006) 935-941
52. Gershov D., Kim S., Brot N., et al. C-Reactive protein binds to apoptotic cells, protects the cells from assembly of the terminal complement components, and sustains an antiinflammatory innate immune response: implications for systemic autoimmunity. J Exp Med 192 (2000) 1353-1364
53. Shoenfeld Y. Idiotypic induction of autoimmunity: do we need an autoantigen?. Clin Exp Rheumatol 12 Suppl 11 (1994) S37-S40
54. Wang Q., Zhu X., Xu Q., et al. Effect of C-reactive protein on gene expression in vascular endothelial cells. Am J Physiol Heart Circ Physiol 288 (2005) H1539-H1545
55. Devaraj S., Xu D.Y., and Jialal I. C-reactive protein increases plasminogen activator inhibitor-1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation 107 (2003) 398-404
56. Austin III H.A., Boumpas D.T., Vaughan E.M., et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histologic data. Kidney Int 45 (1994) 544-550
57. Bellomo III R., Ronco C., Kellum J.A., et al. Acute renal failure-definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group. Crit Care 8 (2004) R204-R212